Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2025 According to Nielsen BioSciences media release, the company is planning regulatory submissions in the US following the successful conclusion of the trial and has partnered with Maruho Co., Ltd. for the regulatory submission and commercialization of CANDIN in Japan.
26 Feb 2025 According to Nielsen BioSciences media release, results are expected by the end of 2025.
26 Feb 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com